Immuneering Corp key statistics and ratios
In fiscal 2023, Immuneering Corp had return on equity of -53.4%, debt equal to 0.0% of equity and a current ratio of 11.35. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 |
|---|---|---|---|---|
| Gross margin | 44.6% | 44.6% | 50.1% | — |
| Operating margin | −739.0% | <−999% | <−999% | — |
| Net margin | −737.2% | <−999% | <−999% | — |
| Free-cash-flow margin | −634.8% | <−999% | <−999% | — |
| Return on equity | — | −50.2% | −38.0% | −53.4% |
| Return on assets | −44.3% | −32.7% | −34.9% | −47.5% |
| Asset turnover | 0.06 | 0.02 | 0.00 | — |
| Current ratio | 16.73 | 27.04 | 13.50 | 11.35 |
| Debt to equity | — | 0.0% | 0.0% | 0.0% |
| R&D as % of revenue | 649.1% | >999% | >999% | — |
| Capital spending as % of revenue | 2.3% | 2.9% | 234.3% | — |
| Quarter | 2022 Q1Mar 2022 | 2022 Q2Jun 2022 | 2022 Q3Sept 2022 | 2022 Q4Dec 2022 | 2023 Q1Mar 2023 | 2023 Q2Jun 2023 | 2023 Q3Sept 2023 | 2023 Q4Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 50.5% | 49.2% | 49.6% | 100.0% | — | — | — | — |
| Operating margin | <−999% | <−999% | <−999% | <−999% | — | — | — | — |
| Net margin | <−999% | <−999% | <−999% | <−999% | — | — | — | — |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | — | — | — | — |
| Current ratio | 37.98 | 33.99 | 16.54 | 13.50 | 17.05 | 20.35 | 17.89 | 11.35 |
| R&D as % of revenue | >999% | >999% | >999% | >999% | — | — | — | — |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
More: Biotechnology stocks compared, Health Care sector, rankings of US companies